Business context and reporting period
This is Galena Biopharma, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2015, filed August 6, 2015. The request identifies SELLAS Life Sciences Group, Inc.; the supplied filing is for Galena Biopharma, so confirm the issuer and filing match your intended review.
Galena was developing oncology candidates, led by NeuVax, and commercializing Abstral. Zuplenz was launched on July 29, 2015, after the reporting date; it generated no revenue in the periods presented.
Financial performance and position
| Metric | Q2 2015 | Q2 2014 | Six months 2015 | Six months 2014 |
|---|---|---|---|---|
| Net revenue | $3.382 million | $2.331 million | $6.132 million | $4.504 million |
| Operating loss | $11.269 million | $15.783 million | $22.395 million | $27.632 million |
| Net loss | $15.660 million | $19.941 million | $26.197 million | $22.477 million |
| Net loss per share | $(0.10) | $(0.17) | $(0.18) | $(0.19) |
| Net cash used in operating activities | Not separately provided for the quarter | $23.415 million | $21.020 million |
- Q2 revenue rose 45%; six-month revenue rose 36%, primarily from Abstral. Management cited higher prescription demand and improved gross-to-net deductions following its patient support and assistance-program changes.
- Q2 cost of revenue excluding acquired-intangible amortization was $0.468 million, or 14% of revenue; amortization was $0.442 million. For six months, these were $0.861 million (14%) and $0.588 million, respectively.
- Q2 operating loss improved by $4.514 million year over year. Six-month operating loss improved by $5.237 million, but six-month net loss increased by $3.720 million, principally because a prior-year non-cash warrant fair-value gain became a current-period loss.
- At June 30, cash and cash equivalents were $45.279 million, versus $23.650 million at year-end 2014. Current assets were $51.122 million and current liabilities $38.114 million. Debt totaled $6.625 million: $4.079 million current and $2.546 million long-term. The loan bears 8.45% interest and matures in November 2016.
- Cash from financing activities was $45.613 million for the six months, including proceeds from equity issuance; operating cash use was $23.415 million and investing cash use was $0.569 million. The March offering generated approximately $40.8 million net proceeds. The balance sheet also included $18.794 million of potentially cash-settleable warrant liabilities.
- Common shares outstanding were 162.391 million at June 30; 22.308 million warrants and 11.411 million options were outstanding. The March financing and other share issuances materially expanded the share count.
Changes, outlook, and material developments
- Management expected approximately $15 million of 2015 net revenue from commercial products, with no assurance the target would be achieved. It said cash, together with commercial revenue, should fund operations for at least one year, based on current plans and assumptions. The company expected continuing operating losses and said additional financing might be needed if revenue or funding proved inadequate.
- NeuVax Phase 3 PRESENT enrollment was completed at 758 patients, above the protocol target of 700. Management expected the primary endpoint in 2018, subject to the trial’s event and follow-up criteria.
- GALE-301 Phase 2a early results were described as promising, but the trial was not powered to establish efficacy. The reported two-year disease-free-survival estimates were 85.7% for the 1,000-mcg group and 19.2% for controls (p=0.09); more mature data were expected in fall 2015.
- GALE-401 Phase 2 top-line results in 18 patients showed a reported platelet response rate of 78%; management expected further data later in 2015. It viewed the FDA 505(b)(2) pathway as acceptable for development, not as an approval assurance.
- Key risks include continuing losses and funding dependence; clinical and regulatory uncertainty; commercial execution and product profitability; customer and pharmacy concentration; patent protection and competition; and possible dilution from outstanding warrants and options.
- Legal and regulatory matters include an SEC investigation concerning use of outside investor-relations professionals, shareholder derivative litigation, and patent litigation over potential generic Abstral. Galena reported no litigation liability at June 30; insurers were reserving coverage rights, though substantially all defense fees were being reimbursed subject to those reservations. Galena was responsible for 88% of specified Abstral patent-litigation costs.
- The reported increase in warrant fair value produced a $4.267 million Q2 non-cash loss and a $3.115 million six-month loss. These amounts affected net loss but were not operating cash outflows.
Important facts for investors to verify
- Confirm the filing issuer: this document names Galena Biopharma, not SELLAS Life Sciences Group.
- Check the basis and achievability of the approximately $15 million 2015 revenue outlook, and subsequent Zuplenz launch and sales performance.
- Assess cash runway against operating burn, debt service, clinical commitments, and the company’s stated one-year funding estimate.
- Review the terms, settlement provisions, and potential dilution of the $18.794 million warrant liability and outstanding warrants.
- Track PRESENT trial timing and outcomes, and interpret GALE-301 and GALE-401 preliminary data in light of their study designs and limitations.
- Monitor Abstral generic litigation, the SEC investigation, derivative litigation, insurance coverage, and any resulting costs or liabilities.